Citations Report

Citation Index - Clinical Investigation [920 Articles]

The articles published in Clinical Investigation have been cited 920 times by eminent researchers all around the world. Following is the list of articles that have cited the articles published in Clinical Investigation.

  • Freidlin B, Korn EL (2014) Biomarker enrichment strategies: matching trial design to biomarker credentials. Nature reviews Clinical oncology 11: 81-90.

    View at Publisher | View at Google Scholar
  • 田平武, 松本信英, 金海峰. シンポジウム 32―3 神経疾患に対する抗体療法 アルツハイマー病に対する抗体療法. 臨床神経学. 2011;51(11):1160-1.

    View at Publisher | View at Google Scholar
  • 田平武. Aβ を標的とする Alzheimer 病の免疫療法. 神経治療学. 2016;33(3):415-9.

    View at Publisher | View at Google Scholar
  • Atkinson AC (2014) Selecting a biased-coin design. Statistical Science 29: 144-63.

    View at Publisher | View at Google Scholar
  • 周军, 夏春, 沈勤, 印洪林, 张新华, 石群立, 周晓军, 马捷. 胃肠道侵袭性 B 细胞淋巴瘤临床病理学研究. 中华病理学杂志. 2014:8-14.

    View at Publisher | View at Google Scholar
  • Antognini AB, Giovagnoli A (2015) Adaptive designs for sequential treatment allocation. CRC Press; 2015 Apr 6.

    View at Publisher | View at Google Scholar
  • Sverdlov O (2015) An Overview of Adaptive Randomization Designs in Clinical Trials. InModern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects 30: 3-44.

    View at Publisher | View at Google Scholar
  • 周军, 马捷. c-myc 基因在侵袭性 B 细胞淋巴瘤中的研究进展. 中华病理学杂志. 2013;42:786-788.

    View at Publisher | View at Google Scholar
  • Zhang LX (2015) Response–Adaptive Randomization: An Overview of Designs and Asymptotic Theory. InModern Adaptive Randomized Clinical Trials: Statistical and Practical 30: 221-249.

    View at Publisher | View at Google Scholar
  • Kim MM, Parmar H, Cao Y, Pramanik P, Schipper M, Hayman J, Junck L, Mammoser A, Heth J, Carter CA, Oronsky A. Whole brain radiotherapy and RRx-001: two partial responses in radioresistant melanoma brain metastases from a phase I/II clinical trial: a TITE-CRM phase I/II clinical trial. Translational oncology. 2016 Apr 30;9(2):108-13.

    View at Publisher | View at Google Scholar
  • Banwell BL (2016) UNIVERSITY OF PENNSYLVANIA-PERELMAN SCHOOL OF MEDICINE.

    View at Publisher | View at Google Scholar
  • Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R. (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. The lancet oncology;13:1011-9.

    View at Publisher | View at Google Scholar
  • Graham R, McCoy MA, Schultz AM (2015)Resuscitation Research and Continuous Quality Improvement. Washington (DC): National Academies Press (US).

    View at Publisher | View at Google Scholar
  • Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F.,et al. (2012) Identifying and targeting ROS1 gene fusions in non–small cell lung cancer. Clinical Cancer Research ;18:4570-79.

    View at Publisher | View at Google Scholar
  • Yushan Shan, Zhang Lele, Zhang Haiying, Hu Xiaoguang, Zhang Weixi, et al. (2013) The value of enzyme-linked immunospot assay in the diagnosis of tuberculosis in children. Journal of Medical Research 42 : 151-4.

    View at Publisher | View at Google Scholar
  • Camidge DR, Doebele RC. (2012)Treating ALK-positive lung cancer—early successes and future challenges. Nature reviews Clinical oncology ;9:268-277.

    View at Publisher | View at Google Scholar
  • Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D’Amico TA, Demmy TL, Dilling TJ.(2015) Non–small cell lung cancer, version 6. Journal of the National Comprehensive Cancer Network ;13:515-524.

    View at Publisher | View at Google Scholar
  • Blanco E, Hargrave D (2014)Can we improve the efficiency of early phase trials in pediatric oncology?. Clinical Investigation 4: 1021-30.

    View at Publisher | View at Google Scholar
  • Atherly AJ, Camidge DR. (2015)The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. British journal of cancer;106:1100-6.

    View at Publisher | View at Google Scholar
  • Kaddar M, Milstien J, Schmitt S (2014) Impact of BRICS? investment in vaccine development on the global vaccine market. Bulletin of the World Health Organization 92:436-46.

    View at Publisher | View at Google Scholar
  • Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F. (2014) ALK inhibitors in the treatment of advanced NSCLC. Cancer treatment reviews ;40:300-306.

    View at Publisher | View at Google Scholar
  • Herter-Sprie GS, Kung AL, Wong KK (2013) New cast for a new era: preclinical cancer drug development revisited. The Journal of clinical investigation 123: 3639-45.

    View at Publisher | View at Google Scholar
  • Aisner DL, Marshall CB.(2012) Molecular Pathology of Non–Small Cell Lung Cancer. American journal of clinical pathology;138:332-346.

    View at Publisher | View at Google Scholar
  • Dore GJ, Lawitz E, Hézode C, Shafran SD, Ramji A,et al. (2015) Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology 148:355-66.

    View at Publisher | View at Google Scholar
  • Weickhardt AJ, Rothman MS, Salian‐Mehta S, Kiseljak‐Vassiliades K, Oton AB, Doebele RC, Wierman ME, Camidge DR. (2012) Rapid‐onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer;118:5302-2309.

    View at Publisher | View at Google Scholar
  • Mangion IK, Chen CY, Li H, Maligres P, Chen Y, et al. (2014) Enantioselective Synthesis of an HCV NS5a Antagonist. Organic letters 16:2310-3.

    View at Publisher | View at Google Scholar
  • Pol S, Corouge M, Sogni P (2013) Oral antiviral therapies for chronic hepatitis C infection. Therapeutic advances in infectious disease 1:107-16.

    View at Publisher | View at Google Scholar
  • O'Bryant CL, Wenger SD, Kim M, Thompson LA. (2013)Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. Annals of Pharmacotherapy:189-197.

    View at Publisher | View at Google Scholar
  • Guedj J, Dahari H, Uprichard SL, Perelson AS (2013) The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate. Expert review of gastroenterology & hepatology 7:397-9.

    View at Publisher | View at Google Scholar
  • Cagle PT, Zhai QJ, Murphy L, Low PS. (2013)Folate receptor in adenocarcinoma and squamous cell carcinoma of the lung: potential target for folate-linked therapeutic agents. Archives of pathology & laboratory medicine;137:241-244.

    View at Publisher | View at Google Scholar
  • Zhou N, Hernandez D, Ueland J, Yang X, Yu F, et al. (2016) NS5A sequence heterogeneity and mechanisms of daclatasvir resistance in hepatitis C virus genotype 4 infection. Journal of Infectious Diseases 213:206-15.

    View at Publisher | View at Google Scholar
  • Guedj J, Dahari H, Uprichard SL, Perelson AS (2013) The rapid viral decline with the HCV NS5A inhibitor daclatasvir reveals a dual mode of action and leads to a new HCV half-life estimate. Expert review of gastroenterology & hepatology 7:397.

    View at Publisher | View at Google Scholar
  • Weickhardt AJ, Doebele RC, Purcell WT, Bunn PA, Oton AB, Rothman MS, Wierman ME, Mok T, Popat S, Bauman J, Nieva J. (2013) Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer ;119:2383-2390.

    View at Publisher | View at Google Scholar
  • Salvatierra KA (2014) Resistencia a nuevos antivirales de acción directa en aislados clínicos del virus de la hepatitis C.

    View at Publisher | View at Google Scholar
  • Sun H, Li Y, Li D, Hou T. (2013) Insight into crizotinib resistance mechanisms caused by three mutations in ALK tyrosine kinase using free energy calculation approaches. Journal of chemical information and modeling ;53:2376-2389.

    View at Publisher | View at Google Scholar
  • Zhou N, Han Z, Hartman-Neumann S, DeGray B, Ueland J, et al. (2016) Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens. Journal of Antimicrobial Chemotherapy 71: 3495-3505.

    View at Publisher | View at Google Scholar
  • Sherilyn Brinkley NP, Appolo B, DeSanto J, Olson M (2017) New Hepatitis C Therapies.

    View at Publisher | View at Google Scholar
  • Vijayvergia N, Mehra R.(2014) Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer. Cancer chemotherapy and pharmacology;74:437-446.

    View at Publisher | View at Google Scholar
  • Goździk-Spychalska J, Szyszka-Barth K, Spychalski Ł, Ramlau K, Wójtowicz J, Batura-Gabryel H, Ramlau R.(2014) C-MET inhibitors in the treatment of lung cancer. Current treatment options in oncology ;15:670-682.

    View at Publisher | View at Google Scholar
  • Eng L, Qiu X, Su J, Pringle D, Niu C, et al. (2015) The role of second‐hand smoke exposure on smoking cessation in non–tobacco‐related cancers. Cancer 121: 2655-63.

    View at Publisher | View at Google Scholar
  • Schnell P, Bartlett CH, Solomon BJ, Tassell V, Shaw AT, Pas T, Lee SH, Lee GK, Tanaka K, Tan W, Tang Y. (2015) Complex renal cysts associated with crizotinib treatment. Cancer medicine ;4:887-896.

    View at Publisher | View at Google Scholar
  • Natoli S, Lazzari M, Dauri M (2015) Open questions in the treatment of cancer pain: time for a strong evidence-based approach?. View at Publisher | View at Google Scholar
  • West HJ, (2012) Camidge DR. Have Mutation, Will Travel: Utilizing Online Patient Communities and New Trial Strategies to Optimize Clinical Research in the Era of Molecularly Diverse Oncology. Journal of Thoracic Oncology;7:482-484.

    View at Publisher | View at Google Scholar
  • FEBS J (2011) Bibliografía completa. FEBS J 278: 4649-67.

    View at Publisher | View at Google Scholar
  • Morán T, Quiroga V, de los Llanos Gil M, Vilà L, Pardo N, Carcereny E, Capdevila L, Muñoz-Mármol AM, Rosell R.(2013) Targeting EML4-ALK driven non-small cell lung cancer (NSCLC). Translational lung cancer research ;2:128-141.

    View at Publisher | View at Google Scholar
  • Dodgen AL, Hill KD (2015) Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension. Drug, healthcare and patient safety 7:175.

    View at Publisher | View at Google Scholar
  • 朱海波, 徐小玉, 王玲. 克里唑替尼治疗晚期非小细胞肺癌的临床研究进展. 中国肺癌杂志. 2013;16:321-324.

    View at Publisher | View at Google Scholar
  • 朱海波, 徐小玉, 王玲. 克里唑替尼治疗晚期非小细胞肺癌的临床研究进展. 中国肺癌杂志. 2013;16:321-324.

    View at Publisher | View at Google Scholar
  • Hill KD, Henderson HT, Hornik CP, Li JS (2015) Paediatric cardiovascular clinical trials: an analysis of ClinicalTrials. gov and the Food and Drug Administration Pediatric Drug Labeling Database. Cardiology in the young 25:172-80.

    View at Publisher | View at Google Scholar
  • Haibo ZH, Xiaoyu XU, Ling WA.(2013) Clinical Research of Crizotinib in Advanced Non-small Cell Lung Cancer. Chinese Journal of Lung Cancer ;16.

    View at Publisher | View at Google Scholar

Relevant Topics